Retinoblastoma Features Can Be Used to Predict Future Risk
Clinical staging can allow for stratification of clinical risk factors, a study shows.
Ophthalmic Oncology
Ophthalmic Oncology
Latest News
Chemotherapy Approach Improves Lacrimal Gland Adenoid Cystic Carcinoma Survival
Investigators review neoadjuvant intra-arterial cytoreductive chemotherapy for orbital malignancy.
Meibomian Gland Dysfunction Common After Stem Cell Transplant
The prevalence of MGD after allogeneic hematopoietic stem cell transplantation is similar among patients with and without chronic ocular graft-versus-host disease, according to a study.
Bilateral Retinoblastoma Not Affected By Maternal Age, Birth Order
Country income status also appears to have no impact on the development of the condition, compared with the unilateral presentation.
Review: Uveitis Most Frequent Ocular Expression of Hodgkin Lymphoma
Ocular events from Hodgkin lymphoma may include infiltrative, inflammatory, paraneoplastic, and toxic reactions.
Kimmtrak Approved for Unresectable or Metastatic Uveal Melanoma
The approval was based on data from the phase 2 IMCgp100-202 trial that assessed Kimmtrak in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
Individualized Treatments Tied to Favorable Outcomes for Patients With MIAN Cysts
Orbital cysts may be present in approximately 16% of all patients with microphthalmia and anophthalmia, a study suggests.
Cancer Therapy Linked With Sight-Threatening Ocular Adverse Events
Growing use of chimeric antigen receptor T-cell therapy for difficult cases of lymphoma may bring with it specific ocular reactions.
OCT, Histopathological Evaluation of Pterygium Warranted for OSSN Suspicion
Patients should undergo routine tissue pathologic examination in the absence of clinical expertise or high-resolution imaging.
Study Identifies Risk Factors For Nodal Metastasis in Eyelid Sebaceous Carcinoma
A graphical calculating tool can help predict nodal metastasis among patients with meibomian gland carcinoma.
Variability Wide Across Practices for Definitions of At-Risk Retinoblastoma
The decision to offer adjuvant chemotherapy and radiotherapy depends on the definition of “high-risk” retinoblastoma, but this definition varies by practice.
Combo Provides Lasting Benefit in Asymptomatic MBM
The 3-year intracranial progression-free survival rate was 54% in asymptomatic patients and 18.9% in symptomatic patients.
Caregivers of Childhood Cancer Survivors Concerned About COVID-19 Vaccines
Many caregivers of children with a history of cancer expressed COVID-19 vaccine hesitancy early in the vaccine rollout.
Injection Significantly Reduces in Choroidal Melanoma Tumor Growth
Three weekly doses of intravitreal AU-011 led to a significant reduction of tumor growth after a year of treatment.
Aqueous Humor Biomarkers May Be Diagnostic for Vitreoretinal Lymphoma
Researchers evaluate the use of the L265P mutation in the MYD88 gene as a diagnostic tool for vitreoretinal lymphoma.
Immune Checkpoint Inhibitors Linked With Extensive Adverse Ocular Events
The complications were most commonly seen in patients taking ipilimumab.
Most Optic Pathways Gliomas Managed Conservatively
Researchers show visual outcomes of patients with neurofibromatosis type 1 and optic pathways gliomas.
Depression Following Facial Mohs Micrographic Surgery Characterized
Researchers quantified rates of depressive symptoms in the short-term postoperative period using PHQ-8 scores at baseline and at follow-up intervals.
Biopsy, Not Flow Cytometry, Is Best for Diagnosing Orbital Lymphoma
Researchers reported that flow cytometry from fresh frozen biopsy tissue as a diagnostic test only rendered a positive result 55% of the time.
Pagetoid Intraepithelial Neoplasia Linked With Tumor-Related Mortality
Researchers examined clinical characteristics and prognosis of patients with pagetoid, bowenoid, or papillary intraepithelial growth patterns.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Ophthalmic Oncology
Loading... 
Loading...